Literature DB >> 1693497

Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group.

.   

Abstract

The persistence and recurrence of choroidal neovascularization after initial treatment with laser photocoagulation have been shown to be major contributors to loss of visual acuity. The 247 eyes assigned to krypton red laser photocoagulation in the Age-Related Macular Degeneration Study-Krypton Laser were examined to describe the incidence, timing, visual impact, and potential risk factors for persistence and recurrence. Persistent neovascularization detected within 6 weeks of initial treatment was observed in 32% of treated eyes, and recurrent neovascularization was estimated by life-table methods to develop in an additional 47% over a 5-year period. Both persistence and recurrence were accompanied by an increased frequency of severe visual loss. The persistence rate among eyes having 10% or more of the foveal side of the neovascular membrane not covered by treatment was twice as high as in eyes having more extensive coverage. Patients having a fellow eye with a neovascular membrane or scar, a fellow eye with 20 or more drusen in the central macula, or a fellow eye with nongeographic atrophy at initial visit had more recurrences than patients without these characteristics. Ophthalmologists treating similar lesions may be able to reduce persistent neovascularization and the associated visual loss by covering the entire lesion with treatment.

Entities:  

Mesh:

Year:  1990        PMID: 1693497     DOI: 10.1001/archopht.1990.01070080067037

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  15 in total

1.  The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1.

Authors: 
Journal:  Control Clin Trials       Date:  1999-12

2.  The Age-Related Eye Disease Study: a clinical trial of zinc and antioxidants--Age-Related Eye Disease Study Report No. 2.

Authors: 
Journal:  J Nutr       Date:  2000-05       Impact factor: 4.798

3.  Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Julie E Buring
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

4.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

5.  A pilot study of ICG-guided laser photocoagulation for occult choroidal neovascularization presenting as a focal spot in age-related macular degeneration.

Authors:  S Da Pozzo; M B Parodi; G Ravalico
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

Review 6.  Complement, age-related macular degeneration and a vision of the future.

Authors:  Karen M Gehrs; Jared R Jackson; Eric N Brown; Rando Allikmets; Gregory S Hageman
Journal:  Arch Ophthalmol       Date:  2010-03

7.  Laser treatment in 341 patients with exudative age-related macular degeneration.

Authors:  Leyla Atmaca; Aysun Idil; Pelin Atmaca-Sönmez
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

Review 8.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Treatment of neovascular age-related macular degeneration: Current therapies.

Authors:  Albert J Augustin; Stefan Scholl; Janna Kirchhof
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?

Authors:  R Machemer; U H Steinhorst
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.